Cardiogenic Shock Remains Higher in Comorbid ACS, Diabetes
Patients with acute coronary syndrome and diabetes have significantly higher rates of cardiogenic shock and lower rates of revascularization.
Metabolic
Pharmacodynamics of Adjunctive Vorapaxar With DAPT in Type 2 Diabetes
Investigators examined the effects of vorapaxar on thrombotic cardiovascular events in patients with atherosclerotic disease and type 2 diabetes.
How Do Patterns of Change in Cardiovascular Health Affect Risk for T2D?
Changes in cardiovascular health over time may affect risk for type 2 diabetes and impaired fasting glucose.
ESC Updates Guidelines for Managing CVD in Those With Diabetes
In updated guidelines developed by the ESC, in collaboration with the European Association for the Study of Diabetes, recommendations are presented for the prevention and management of CVD in diabetes.
Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial
The Medicines Company announced topline results from the pivotal phase 3 ORION-11 study that evaluated the efficacy and safety of inclisiran.
Managing Hypertriglyceridemia With Omega-3 Fatty Acids: An AHA Advisory
The advisory from the American Heart Association aggregates the research performed thus far on the use of omega-3 fatty acids in hypertriglyceridemia and recommends a dose of 4 g/d to observe a therapeutic effect.
Lomitapide Reduces LDL-C Levels in Homozygous Familial Hypercholesterolemia
Lomitapide reduced low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, with some patients reaching recommended targets.
Higher Total Cholesterol and LDL-C Levels Associated With Lower WBC Count
There are modest associations between higher lipid levels and circulating leukocyte counts in humans.
Decline in Cardiometabolic Disease Mortality Rates Slowing
From 2010 to 2017, no significant change was seen in age-adjusted mortality rates for stroke or diabetes.
Metabolic Syndrome and CV Risk Management After Liver Transplantation
Significant improvements to the management of metabolic syndrome after liver transplantation must be made to reduce the risk for CV events and mortality.
Next post in Metabolic
